Mizuho Securities selects Regenxbio Inc as November small-cap biotech pick
RGNX Regenxbio Inc
$7.69 -4.71%
View chart & analysis → - 1Mizuho Securities raised its price target for Regenxbio Inc from 7.71 to 18.00 and maintained an Outperform rating.
- 2Regenxbio Inc recorded 9.2 million in revenue for the third quarter, exceeding Mizuho Securities' expectations.
- 3AbbVie is conducting a global Phase 3b study for sura-vec involving approximately 560 patients.
So what's the key point?
Mizuho Securities expects Regenxbio Inc's stock to rise because its revenue was higher than expected. Experts have raised the target price to 18.00.
Source Investing.com · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.